Form 4: Acadia Director Sells 30,000 Shares in Pre-Planned Transaction

Acadia Pharmaceuticals Director James M. Daly sold 30,000 shares of common stock for approximately $22.37 per share in a pre-scheduled transaction.

Summary

• James M. Daly, a Director of ACADIA PHARMACEUTICALS INC (ACAD), reported a sale of common stock.
• The transaction occurred on November 10, 2025.
• Daly disposed of 30,000 shares of ACAD common stock.
• The shares were sold at a weighted average price of $22.3661 per share, with prices ranging from $22.14 to $22.63.
• Following this transaction, Daly beneficially owns 4,041 shares of ACAD common stock.
• The sale was conducted pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 4

Explanation: The sale of 30,000 shares by a director, even under a Rule 10b5-1 plan, can be perceived as a mild negative signal by investors, suggesting the insider may view the stock as fully valued or is diversifying holdings. However, the pre-planned nature reduces the immediate negative impact compared to an unplanned sale.

Negatives

• A director selling 30,000 shares could be perceived negatively by the market, potentially signaling a belief that the stock is fully valued or a desire for diversification.
• The sale reduces the director's direct beneficial ownership to 4,041 shares.

Future Outlook

N/A

Industry Context

N/A

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the director's sale as a signal regarding the stock's valuation or future prospects, potentially leading to selling pressure.

Key Dates

Recommendation

The sale of 30,000 shares by Director James M. Daly, while notable, was executed under a Rule 10b5-1 plan, which suggests a pre-scheduled diversification or liquidity event rather than a reaction to new, negative material non-public information. While insider sales can sometimes signal a lack of confidence, the pre-planned nature mitigates this concern. Investors should monitor future insider activity and company fundamentals, but this single transaction does not warrant an immediate 'sell' recommendation. A 'hold' stance is appropriate, pending further developments.

Keywords

ACADIA PHARMACEUTICALS, ACAD, Form 4, Insider Sale, Director Transaction, Stock Sale, Beneficial Ownership, Rule 10b5-1